ArticleWorld journal of surgical oncology2026
A prognostic model utilizing disulfidptosis-related long noncoding RNAs to differentiate pathological grades in hepatocellular carcinoma: functional analysis of AL031985.3.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfidptosis, a recently identified form of cell death, plays a crucial role in cancer progression, specifically by altering intracellular disulfide bonds within the actin cytoskeleton. Our research centres on developing a prognostic model based on disulfidptosis-related long noncoding RNAs (DRLRs) to differentiate high-grade (G3-G4) from low-grade (G1-G2) Hepatocellular Carcinoma (HCC). Utilizing transcriptomic data from The Cancer Genome Atlas (TCGA), we employed univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator(LASSO) regression, and multivariate Cox regression to ultimately identify nine key drlncRNAs (AL442125.2, AC018529.2, AL031985.3, AC119150.1, LINC02256, AC026979.4, POLH-AS1, MED8-AS1, and AC026356.1). These were subsequently used to construct a prognostic risk signature model. This 9-DRLR model demonstrated robust discriminative capacity, achieving Area Under the Curve(AUCs) of 0.845, 0.841, and 0.885 for 1-, 3-, and 5-year overall survival prediction in G3-G4 HCC patients, respectively. The model provides strong prognostic stratification of HCC patients by grade and correlates with biological processes linked to tumour aggressiveness and immune evasion, as shown by Gene Ontology (GO) and gene set enrichment analyses (GSEA). High-risk groups exhibited markers of immune dysfunction, elevated tumour mutation burden (TMB), and increased sensitivity to targeted therapies including 5-Fluorouracil and Dasatinib. AL031985.3 emerged as a key lncRNA within this model, with its significant overexpression in HCC tissues versus adjacent controls (p < 0.001) validated through quantitative Real-Time PCR (qRT-PCR). Functional analyses revealed AL031985.3 as a critical oncogenic driver, where its knockdown significantly suppressed colony formation (p < 0.01) and reduced invasive capacity (p < 0.01) in vitro. These findings were corroborated in vivo, with orthotopic implantation and experimental pulmonary metastasis models demonstrating attenuated tumour growth and modulated epithelial-mesenchymal transition markers following AL031985.3 silencing. Our findings underscore the prognostic value of the DRLR signature and establish AL031985.3 as a potential therapeutic target for advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.